The objective of this study was to determine if the maternal serum levels of visfatin in the first trimester of pregnancy are altered in cases that develop preeclampsia (PE) and whether the levels are related to placental perfusion reflected in uterine artery pulsatility index (PI). Serum visfatin and uterine artery PI were measured at 11(+0)-13(+6) weeks in 80 cases that developed PE and 240 unaffected controls. The median visfatin and uterine artery PI multiple of the unaffected median (MoM) in the outcome groups was compared and the significance of the association between visfatin MoM and uterine artery PI MoM, birth weight percentile and gestation at delivery was determined. In the PE group, compared with controls, there was a significantly higher median visfatin MoM (1.35, interquartile range (IQR): 0.69-2.16 vs 1.00, IQR: 0.55-1.96, P=0.027) and uterine artery PI MoM (1.19, IQR: 0.95-1.44 vs 1.03, IQR: 0.83-1.22, P<0.0001). In the PE group, there was no significant association between serum visfatin MoM and uterine artery PI MoM (P=0.589), gestation at delivery (P=0.763) or birth weight percentile (P=0.646). Serum visfatin levels at 11-13 weeks are increased in women who develop PE by a mechanism unrelated to impaired placental perfusion.
Different studies show that small non-coding RNAs, such as microRNAs (miRNAs) obtained from exosomes, are considered potential biomarkers in several types of cancer, including cervical cancer (CC). Therefore, the present study seeks to present an overview of the role of circulating exosomal miRNAs with the potential to act as biomarkers for the diagnosis and prognosis of CC and to analyze the presence of these miRNAs according to the stage of CC. For this purpose, a review was developed, with articles consulted from the electronic databases MEDLINE/PubMed, Scopus, and Web of Science published between 2015 and 2021. Seven articles were included after a selection of studies according to the eligibility criteria. In addition to the methods used for sample analysis, detection, and isolation of miRNAs in each article, clinical data were also extracted from the patients studied, such as the stage of cancer. After analyzing the network of the seven miRNAs, they were associated with the immune system, CC progression and staging, and cisplatin resistance. With the belief that studies on miRNAs in cervical cancer would have major clinical implications, in this review, we have attempted to summarize the current situation and potential development prospects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.